We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares

Delisted

RVLP was delisted on the 20th of October, 2023.

41 hedge funds and large institutions have $28.7M invested in RVL Pharmaceuticals plc Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

14% more funds holding

Funds holding: 3641 (+5)

3% more capital invested

Capital invested by funds: $27.9M → $28.7M (+$794K)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
0.65%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
3
Reduced
10
Closed
2
Calls
$186K
Puts
Net Calls
+$186K
Net Calls Change
-$7K
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
26
Jane Street
New York
$20.3K +$21.3K +17,785 New
Wells Fargo
27
Wells Fargo
California
$17.4K -$1.8K -1,497 -9%
Barclays
28
Barclays
United Kingdom
$15.6K -$11.5K -9,620 -41%
Charles Schwab
29
Charles Schwab
California
$15.2K
Bank of New York Mellon
30
Bank of New York Mellon
New York
$13.8K
Squarepoint
31
Squarepoint
New York
$12.9K +$13.6K +11,299 New
SWA
32
SFMG Wealth Advisors
Texas
$11.4K
WJWM
33
Williams Jones Wealth Management
New York
$11.4K
TVWM
34
Tower View Wealth Management
Wisconsin
$5K
DCBT
35
Dakota Community Bank & Trust
North Dakota
$4.54K +$4.78K +3,980 New
TRCT
36
Tower Research Capital (TRC)
New York
$3K +$3.17K +2,645 New
Bank of America
37
Bank of America
North Carolina
$1.96K
Osaic Holdings
38
Osaic Holdings
Arizona
$1.35K
UBS Group
39
UBS Group
Switzerland
$257 -$1.39K -1,157 -84%
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$8
VF
41
Virtu Financial
New York
-$45K -39,818 Closed
Two Sigma Advisers
42
Two Sigma Advisers
New York
-$15.8K -14,100 Closed

RVLP Hedge Fund Activity: Q1 2023 in Review

41 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2023, worth a combined $28.7M — up 2.8% from $27.9M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new RVLP positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 10 trimmed.

The largest buyer was Scoggin Management, opening a new position worth an estimated $600K. The largest seller was AIGH Capital Management, cutting an estimated $655K.

  • 41 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2023, up from 36 in Q4 2022.
  • Funds reported $28.7M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2023, up 2.8% quarter-over-quarter.
  • 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2023 and 2 closed out, a net change of +6 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2023 was Scoggin Management, an estimated $600K added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2023 was AIGH Capital Management, an estimated $655K sold.

Based on aggregated 13F filings for Q1 2023.